Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0472-0147 · 1 trial · 2 indications
Number of events
Number of events
| Arm | Type | Description |
|---|---|---|
| NNC0472-0147 Part 1 | EXPERIMENTAL | Part 1: Each cohort will consist of 8 healthy subjects - 6 subjects will receive a single subcutaneous (s.c., under the skin) dose of NNC0472-0147. |
| Placebo Part 1 | PLACEBO_COMPARATOR | Part 1: Each cohort will consist of 8 healthy subjects - 2 subjects will receive a single s.c. dose of placebo. |
| NNC0472-0147 Part 2 | EXPERIMENTAL | Part 2: Each cohort will consist of 12 subjects with T2DM. 9 subjects will receive once daily s.c. doses of NNC0472-0147 for 14 days |
| Insulin glargine Part 2 | ACTIVE_COMPARATOR | Part 2: Each cohort will consist of 12 subjects with T2DM - 3 subjects will receive once daily s.c. doses of insulin glargine for 14 days. |
| Name | Type | Description |
|---|---|---|
| NNC0472-0147 | DRUG | Part 1: A single dose of NNC0472-0147, dose increased in each cohort. Part 2: Daily doses of NNC0472-0147, dose increased in each cohort. |
| insulin glargine | DRUG | Part 2: A fixed dose level of 0.5 U/kg insulin glargine will be used in all cohorts. |
| Placebo (NNC0472-0147) | DRUG | Part 1: A single dose of placebo, dose increased in each cohort. |
Inclusion Criteria: Part 1: * Male * Aged 18-55 years (both inclusive) at the time of signing nformed consent. Part 2: * Male, or female of non-child bearing potential. Non-child bearing potential is defined by being surgically sterilised (documented hysterectomy, bilateral salpingectomy or bila...
NNC0472-0147 is an investigational small molecule being developed by Novo Nordisk A/S for the treatment of type 2 diabetes mellitus. It is in Phase 1 clinical development and has been studied in a single completed trial that enrolled 36 participants, including healthy volunteers and people with type 2 diabetes.
NNC0472-0147 is being evaluated as a potential treatment for type 2 diabetes mellitus. It is an investigational therapy and has not been approved for any indication. The completed Phase 1 trial included people with type 2 diabetes alongside healthy volunteers to assess the drug in both populations.
NNC0472-0147 is developed by Novo Nordisk A/S, a pharmaceutical company traded under the ticker NVO. Novo Nordisk is the sponsor of the Phase 1 clinical trial evaluating the compound in healthy volunteers and people with type 2 diabetes.
NNC0472-0147 is in Phase 1 clinical development. It is an investigational small molecule and is not approved for any indication. One Phase 1 trial has been completed, and no active trials are currently listed for this compound.
NNC0472-0147 has been studied in one completed Phase 1 trial, NCT04262661, titled a study to look at how safe NNC0472-0147 is in healthy people and in people with type 2 diabetes. The trial enrolled 36 participants in Germany and was randomized, double-blind, and placebo-controlled.